Table 1.
Baseline characteristics of the study patients.
| Characteristic | |
|---|---|
| Age of recipient (years) (median (range)) | 48 (20–77) |
| Gender (male) | n = 90 (65%) |
| Type of Transplant | |
| Kidney | n = 133 (96.4%) |
| Kidney + pancreas | n = 4 (2.9%) |
| Kidney + heart | n = 1 (0.7%) |
| Type of Donor | |
| Living | n = 10 (7.2%) |
| Deceased | n = 128 (92.8%) |
| Pretransplant Donor (D)/Recipient (R) CMV Serostatus | |
| D+/R− | n = 34 (25.2%) |
| D− or D+/R+ | n = 104 (74.8%) |
| Induction Therapy | |
| Thymoglobulin | n = 13 (9.4%) |
| Basiliximab | n = 72 (52.2%) |
| None | n = 53 (38.4%) |
| Maintenance Immunosuppression | |
| tacrolimus + mycophenolate mofetil/sodium + prednisone | n = 121 (87.7%) |
| cyclosporine A + mycophenolate mofetil/sodium + prednisone | n = 15 (10.9%) |
| tacrolimus + everolimus + prednisone | n = 2 (1.4%) |
| Time from kidney transplant to antiviral prophylaxis initiation (days) (mean ± SD [range]) | 6 ± 5 (0–25) |
| Time from kidney transplant to antiviral prophylaxis discontinuation (days) (mean ± SD [range]) | 90 ± 21 (12–178) |
| Duration of antiviral prophylaxis (days) (mean ± SD (range)) | 84 ± 21(10–175) |
| Allograft function (eGFR; ml/min/1.73 m2) (mean ± SD [range]) | |
| Day 30 | 46.7 ± 19.9 (6.7–103.7) |
| Day 90 | 47.8 ± 18.5 (8.5–98.9) |
| Day 360 | 49.5 ± 18.6 (8.8–105.0) |
| KIR Genotype | |
| A/A | n = 42 (30.4%) |
| B/X | n = 96 (69.6%) |
eGFR, estimated glomerular filtration rate; SD, standard deviation.